LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and...
Published
Sat, Jul 17 2010 1:41 PM
by
Tom Moylan
Filed under: consumer products, litigation, torts, lawsuit, personal injury, Glaxo, drugs & devices, drugs, Mealey’s, GSK, GlaxoSmithKline, U.S. Securities and Exchange Commission, Avandia, diabetes drug, paroxetine, Apotex, Paxil, antidepressant, product liability